Helen McIlleron

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2865569/publications.pdf

Version: 2024-02-01

158 papers	7,397 citations	50276 46 h-index	66911 78 g-index
163 all docs	163 docs citations	163 times ranked	6380 citing authors

#	Article	IF	Citations
1	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	10.7	459
2	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
3	Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes. Journal of Infectious Diseases, 2013, 208, 1464-1473.	4.0	378
4	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
5	Global tuberculosis drug development pipeline: the need and the reality. Lancet, The, 2010, 375, 2100-2109.	13.7	319
6	Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2006, 50, 1170-1177.	3.2	222
7	Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2007, 196, S63-S75.	4.0	190
8	Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears. Antimicrobial Agents and Chemotherapy, 2007, 51, 2994-2996.	3.2	183
9	The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. Antimicrobial Agents and Chemotherapy, 2011, 55, 4122-4127.	3.2	130
10	Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption. Antimicrobial Agents and Chemotherapy, 2008, 52, 2138-2148.	3.2	129
11	Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines. Clinical Infectious Diseases, 2009, 48, 1547-1553.	5.8	125
12	Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 38-45.	3.2	123
13	The Early Bactericidal Activities of Rifampin and Rifapentine in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 128-135.	5.6	102
14	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 333-339.	2.1	101
15	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	10.7	92
16	Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines. Antimicrobial Agents and Chemotherapy, 2012, 56, 3232-3238.	3.2	91
17	Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. British Journal of Clinical Pharmacology, 2011, 72, 51-62.	2.4	90
18	Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. New England Journal of Medicine, 2022, 386, 911-922.	27.0	90

#	Article	IF	Citations
19	A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 2091-2098.	3.2	77
20	Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Medicine, 2009, 7, 19.	5.5	73
21	Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS ONE, 2015, 10, e0141002.	2.5	73
22	Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. Journal of Antimicrobial Chemotherapy, 2007, 61, 389-393.	3.0	72
23	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antiviral Therapy, 2009, 14, 687-695.	1.0	72
24	Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2018, 73, 2305-2313.	3.0	71
25	Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. European Journal of Clinical Pharmacology, 2006, 62, 727-735.	1.9	69
26	Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection. Journal of Infectious Diseases, 2015, 211, 197-205.	4.0	69
27	Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infectious Diseases, The, 2015, 15, 711-720.	9.1	66
28	Pharmacogenetics of plasma efavirenz exposure in HIVâ€infected adults and children in South Africa. British Journal of Clinical Pharmacology, 2015, 80, 146-156.	2.4	64
29	Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2015, 60, 549-556.	5.8	62
30	Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrobial Agents and Chemotherapy, 2016, 60, 487-494.	3.2	61
31	Standardized methods for enhanced quality and comparability of tuberculous meningitis studies. Clinical Infectious Diseases, 2017, 64, ciw757.	5.8	61
32	Principles for designing future regimens for multidrug-resistant tuberculosis. Bulletin of the World Health Organization, 2014, 92, 68-74.	3.3	60
33	QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infectious Diseases, The, 2021, 21, 975-983.	9.1	60
34	Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients. PLoS Medicine, 2006, 3, e444.	8.4	59
35	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clinical Infectious Diseases, 2020, 70, 1774-1780.	5.8	59
36	Paediatric use of second-line anti-tuberculosis agents: A review. Tuberculosis, 2012, 92, 9-17.	1.9	56

#	Article	IF	Citations
37	The pyrazinamide susceptibility breakpoint above which combination therapy fails. Journal of Antimicrobial Chemotherapy, 2014, 69, 2420-2425.	3.0	56
38	Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis. Antiviral Therapy, 2011, 16, 417-421.	1.0	53
39	Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Journal of Antimicrobial Chemotherapy, 2014, 69, 1339-1349.	3.0	53
40	Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrobial Agents and Chemotherapy, 2016, 60, 2171-2179.	3.2	53
41	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 2019, 58, 747-766.	3.5	53
42	A Review of Moxifloxacin for the Treatment of Drugâ€Susceptible Tuberculosis. Journal of Clinical Pharmacology, 2017, 57, 1369-1386.	2.0	52
43	Nutritional Supplementation Increases Rifampin Exposure among Tuberculosis Patients Coinfected with HIV. Antimicrobial Agents and Chemotherapy, 2014, 58, 3468-3474.	3.2	51
44	Redefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 6111-6115.	3.2	51
45	Drugâ€“drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. Journal of Antimicrobial Chemotherapy, 2016, 71, 1037-1040.	3.0	50
46	Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. Antimicrobial Agents and Chemotherapy, 2011, 55, 3195-3200.	3.2	49
47	Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Medicine, 2013, 11, 253.	5.5	48
48	Pharmacokinetics of Ofloxacin and Levofloxacin for Prevention and Treatment of Multidrug-Resistant Tuberculosis in Children. Antimicrobial Agents and Chemotherapy, 2014, 58, 2948-2951.	3.2	47
49	Pediatric tuberculous meningitis: Modelâ€based approach to determining optimal doses of the antiâ€tuberculosis drugs rifampin and levofloxacin for children. Clinical Pharmacology and Therapeutics, 2015, 98, 622-629.	4.7	47
50	Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 4230-4237.	3.2	46
51	<scp>d</scp>-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clinical Infectious Diseases, 2018, 67, S308-S316.	5.8	45
52	Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. Journal of Antimicrobial Chemotherapy, 2015, 70, 543-549.	3.0	42
53	Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clinical Infectious Diseases, 2017, 64, 1350-1359.	5.8	40
54	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antiviral Therapy, 2009, 14, 687-95.	1.0	40

#	Article	IF	Citations
55	Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 503-510.	3.2	38
56	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Journal of Antimicrobial Chemotherapy, 2017, 72, 1441-1449.	3.0	38
57	Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nature Communications, 2021, 12, 2899.	12.8	38
58	Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discovery Today, 2007, 12, 980-989.	6.4	35
59	Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 3390-3394.	3.2	35
60	A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture. Antimicrobial Agents and Chemotherapy, 2013, 57, 789-795.	3.2	34
61	Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacology & Toxicology, 2014, 15, 61.	2.4	34
62	Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infectious Diseases, The, 2016, 16, 169-179.	9.1	33
63	Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018, 19, 237.	1.6	33
64	Population Pharmacokinetics and Pharmacodynamics of Ofloxacin in South African Patients with Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 3857-3863.	3.2	32
65	Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. Antimicrobial Agents and Chemotherapy, 2016, 60, 1234-1241.	3.2	32
66	Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics, 2019, 20, 225-240.	1.3	32
67	Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. European Journal of Clinical Pharmacology, 2009, 65, 71-80.	1.9	30
68	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. Antimicrobial Agents and Chemotherapy, 2012, 56, 4471-4473.	3.2	30
69	Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infectious Diseases, 2018, 18, 488.	2.9	30
70	The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy. PLoS ONE, 2012, 7, e32173.	2.5	29
71	Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, 2015, 60, 1860-1863.	5.8	28
72	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. British Journal of Clinical Pharmacology, 2016, 82, 185-198.	2.4	28

#	Article	IF	Citations
73	Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	28
74	Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. Journal of Infectious Diseases, 2015, 211, S115-S125.	4.0	27
75	Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. Journal of Antimicrobial Chemotherapy, 2007, 60, 1398-1401.	3.0	26
76	Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. EBioMedicine, 2015, 2, 1640-1649.	6.1	26
77	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clinical Infectious Diseases, 2017, 64, 1597-1603.	5.8	26
78	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 2018, 57, 591-599.	3.5	26
79	Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clinical Infectious Diseases, 2018, 67, S349-S358.	5.8	26
80	HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6050-6059.	3.2	25
81	Current research toward optimizing dosing of first-line antituberculosis treatment. Expert Review of Anti-Infective Therapy, 2019, 17, 27-38.	4.4	25
82	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC Infectious Diseases, 2010, 10, 83.	2.9	24
83	Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. Aids, 2012, 26, 1523-1528.	2.2	24
84	Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. European Journal of Clinical Pharmacology, 2010, 66, 1017-1023.	1.9	23
85	Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 31-37.	2.1	23
86	Gatifloxacin Pharmacokinetics/Pharmacodynamicsâ€“based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. Clinical Infectious Diseases, 2018, 67, S274-S283.	5.8	23
87	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 3433-3457.	3.0	23
88	N -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	23
89	Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children. Antiviral Therapy, 2012, 17, 25-33.	1.0	22
90	Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Journal of Antimicrobial Chemotherapy, 2018, 74, 139-148.	3.0	21

#	Article	IF	Citations
91	Modelâ€based approach to dose optimization of lopinavir/ritonavir when coâ€administered with rifampicin. British Journal of Clinical Pharmacology, 2012, 73, 758-767.	2.4	20
92	Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatrics, 2014, 14, 39.	1.7	20
93	Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. International Journal of Tuberculosis and Lung Disease, 2016, 20, 915-919.	1.2	20
94	Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
95	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. International Journal of Infectious Diseases, 2021, 105, 688-694.	3.3	20
96	Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 30-33.	1.2	19
97	Lopinavirâ€“ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavirâ€“ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV,the, 2019, 6, e32-e42.	4.7	19
98	PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS. Pediatric Infectious Disease Journal, 2011, 30, 262-265.	2.0	18
99	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 6073-6079.	3.2	17
100	Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organizationâ€“Recommended Weight Band Doses and Formulations. Clinical Infectious Diseases, 2022, 74, 1767-1775.	5.8	17
101	Requirements for the clinical evaluation of new anti-tuberculosis agents in children. International Journal of Tuberculosis and Lung Disease, 2013, 17, 794-799.	1.2	16
102	Nevirapine Concentrations in Preterm and Low Birth Weight HIV-Exposed Infants. Pediatric Infectious Disease Journal, 2014, 33, 1231-1233.	2.0	16
103	Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, 19, 17-29.	1.3	16
104	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	16
105	Artificial intelligenceâ€“derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2018, 67, S284-S292.	5.8	16
106	Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. International Journal of Tuberculosis and Lung Disease, 2018, 22, 537-543.	1.2	16
107	Population Pharmacokinetics of Rifapentine and Its Primary Desacetyl Metabolite in South African Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 4429-4436.	3.2	14
108	Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. Tuberculosis, 2007, 87, 557-564.	1.9	14

#	Article	IF	Citations
109	Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations. Antimicrobial Agents and Chemotherapy, 2013, 57, 4164-4171.	3.2	14
110	Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 161-168.	2.1	14
111	The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 333-335.	1.2	13
112	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
113	Modelâ€based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. British Journal of Clinical Pharmacology, 2013, 76, 741-751.	2.4	12
114	Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 780-786.	1.2	12
115	Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 617-620.	3.2	12
116	Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. Journal of Antimicrobial Chemotherapy, 2020, 75, 1019-1025.	3.0	12
117	Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children. International Journal of Tuberculosis and Lung Disease, 2014, 18, 528-530.	1.2	11
118	Plasma Lopinavir Concentrations Predict Virological Failure in a Cohort of South African Children Initiating a Protease-Inhibitor-Based Regimen. Antiviral Therapy, 2014, 19, 399-406.	1.0	11
119	Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
120	Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. Journal of Infectious Diseases, 2019, 219, 89-100.	4.0	11
121	Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring. Therapeutic Drug Monitoring, 2012, 34, 481-484.	2.0	10
122	Population pharmacokinetic drugâ€“drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy, 2016, 71, 1330-1340.	3.0	10
123	Effect of diurnal variation,CYP2B6genotype and age on the pharmacokinetics of nevirapine in African children. Journal of Antimicrobial Chemotherapy, 2017, 72, 190-199.	3.0	10
124	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	3.2	10
125	Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. Journal of Antimicrobial Chemotherapy, 2017, 72, 2028-2034.	3.0	9
126	Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virusâ€associated tuberculosis. British Journal of Clinical Pharmacology, 2020, 86, 966-978.	2.4	8

#	Article	IF	Citations
127	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. The Lancet Child and Adolescent Health, 2022, 6, 9-10.	5.6	8
128	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicinâ€resistant tuberculosis. British Journal of Clinical Pharmacology, 2022, 88, 3548-3558.	2.4	8
129	Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. Aids, 2017, 31, 905-915.	2.2	7
130	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. Pediatric Infectious Disease Journal, 2018, 37, 1199-1203.	2.0	7
131	Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. International Journal of Audiology, 2020, 59, 219-223.	1.7	7
132	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
133	Lipidâ€based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients. HIV Medicine, 2015, 16, 403-411.	2.2	6
134	Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clinical Infectious Diseases, 2020, 71, 517-524.	5.8	6
135	Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents. Progress in Respiratory Research, 2011, , 191-202.	0.1	5
136	Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resourceâ€limited settings. Journal of the International AIDS Society, 2014, 17, 18979.	3.0	5
137	Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. Journal of Antimicrobial Chemotherapy, 2019, 74, 2347-2351.	3.0	5
138	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
139	A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drugâ€“Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clinical Pharmacology and Therapeutics, 2021, 110, 1057-1065.	4.7	5
140	The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1194-1196.	1.2	4
141	Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatric Infectious Disease Journal, 2016, 35, e378-e383.	2.0	4
142	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 490-495.	3.0	4
143	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, e0027821.	3.2	4
144	Quantitative assessment of the activity of antituberculosis drugs and regimens. Expert Review of Anti-Infective Therapy, 2019, 17, 449-457.	4.4	3

#	Article	IF	Citations
145	Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and Genomics, 2022, 32, 24-30.	1.5	3
146	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Frontiers in Pharmacology, 2021, 12, 722204.	3.5	3
147	Population pharmacokinetics of ethambutol in African children: a pooled analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1949-1959.	3.0	3
148	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 0, , .	3.0	3
149	Pharmacometrics in tuberculosis: progress and opportunities. International Journal of Antimicrobial Agents, 2022, 60, 106620.	2.5	3
150	Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 926-930.	1.2	2
151	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 2022, 88, 403-415.	2.4	2
152	Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy, 2023, 43, 638-649.	2.6	2
153	Treating children with tuberculosisâ€"Using pharmacometrics to do better. British Journal of Clinical Pharmacology, 2022, 88, 894-896.	2.4	1
154	Reply to â€œBreakpoints and Drug Exposure Are Inevitably Closely Linkedâ€• Antimicrobial Agents and Chemotherapy, 2015, 59, 1385-1385.	3.2	0
155	Optimal drug therapies for HIV in pregnant women and in children: Considering pharmacogenetics, drug-drug interactions and formulations. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY81-3.	0.0	0
156	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. Wellcome Open Research, 0, 7, 72.	1.8	0
157	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2022, , e0226421.	3.2	0
158	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. Antimicrobial Agents and Chemotherapy, 2022, , e0013622.	3.2	0